» Articles » PMID: 35411985

COVID-19 in Latin America and the Caribbean: Two Years of the Pandemic

Overview
Journal J Intern Med
Specialty General Medicine
Date 2022 Apr 12
PMID 35411985
Authors
Affiliations
Soon will be listed here.
Abstract

Worldwide, nations have struggled during the coronavirus disease 2019 (COVID-19) pandemic. However, Latin America and the Caribbean faced an unmatched catastrophic toll. As of March 2022, the region has reported approximately 15% of cases and 28% of deaths worldwide. Considering the relatively late arrival of SARS-CoV-2, several factors in the region were determinants of the humanitarian crisis that ensued. Pandemic unpreparedness, fragile healthcare systems, forthright inequalities, and poor governmental support facilitated the spread of the virus throughout the region. Moreover, reliance on repurposed and ineffective drugs such as hydroxychloroquine and ivermectin-to treat or prevent COVID-19-was publicised through misinformation and created a false sense of security and poor adherence to social distancing measures. While there were hopes that herd immunity could be achieved after the region's disastrous first peak, the emergence of the Gamma, Lambda, and Mu variants made this unattainable. This review explores how Latin America and the Caribbean fared during the first 2 years of the pandemic, and how, despite all the challenges, the region became a global leader in COVID-19 vaccination, with 63% of its population fully vaccinated.

Citing Articles

The pharmaceutical suitcase trade and the need for multisectoral regulation-unproven COVID-19 (Ivermectin and HCQ remedies unmask an insidious health danger in a Caribbean Island).

Maharaj S, Dookeeram D, Hosein R, Ramkissoon K, Ramdass A, Franco D Front Public Health. 2024; 12:1353516.

PMID: 39726652 PMC: 11669496. DOI: 10.3389/fpubh.2024.1353516.


Increased Early-Mortality in Children With Solid Tumors During the COVID-19 Pandemic in a Middle-Income Country.

Ramirez O, Piedrahita V, Bolivar S, Grillo K, Linares A, Pardo C Cancer Med. 2024; 13(24):e70483.

PMID: 39711262 PMC: 11803909. DOI: 10.1002/cam4.70483.


In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.

Alvarado-Gamarra G, Alcala-Marcos K, Balmaceda-Nieto P, Visconti-Lopez F, Torres-Balarezo P, Moran-Marinos C Eur J Pediatr. 2024; 183(12):5071-5084.

PMID: 39349752 DOI: 10.1007/s00431-024-05787-x.


Adaptation of WHO COVID-19 guidelines by Caribbean countries and territories.

Evans-Gilbert T, Blades E, Boodoosingh R, Campbell M, Christie C, Manzanero M Bull World Health Organ. 2024; 102(10):699-706.

PMID: 39318885 PMC: 11418840. DOI: 10.2471/BLT.23.290796.


Fatal journeys: causes of death in international travellers in South America.

Allel K, Cabada M, Kiani B, Martin B, Tanabe M, Cadavid Restrepo A J Travel Med. 2024; 32(1).

PMID: 39209328 PMC: 11789196. DOI: 10.1093/jtm/taae119.


References
1.
Munoz-Medina J, Grajales-Muniz C, Salas-Lais A, Fernandes-Matano L, Lopez-Macias C, Monroy-Munoz I . SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020. Microorganisms. 2021; 9(4). PMC: 8071542. DOI: 10.3390/microorganisms9040850. View

2.
Abbey E, Khalifa B, Oduwole M, Ayeh S, Nudotor R, Salia E . The Global Health Security Index is not predictive of coronavirus pandemic responses among Organization for Economic Cooperation and Development countries. PLoS One. 2020; 15(10):e0239398. PMC: 7540886. DOI: 10.1371/journal.pone.0239398. View

3.
Rodeles L, Peverengo L, Benitez R, Benzaquen N, Serravalle P, Long A . Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina. Rev Panam Salud Publica. 2021; 45:e66. PMC: 8216497. DOI: 10.26633/RPSP.2021.66. View

4.
Molento M . COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution. One Health. 2020; 10:100148. PMC: 7313521. DOI: 10.1016/j.onehlt.2020.100148. View

5.
Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View